Collaboration Helps Broaden Access to Pfizer’s Contraceptive, Sayana® Press

Partnership objectives

To help broaden access to a full range of contraceptive options, including subcutaneous injectables such as Pfizer’s all-in-one injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in some of the world’s poorest countries.

An estimated 225 million women in developing countries would like to delay or prevent pregnancy but are not using any method of contraception. An estimated 225 million women in developing countries would like to delay or prevent pregnancy but are not using any method of contraception. Copyright Pfizer

What are the health needs and challenges?

The unmet need for contraception remains high. An estimated 225 million women in developing countries would like to delay or prevent pregnancy but are not using any method of contraception[i]. Common reasons for this include difficulty travelling to health facilities, social barriers, and lack of knowledge around what contraceptive methods are available[ii].

Description of partnership activities and how they address needs and challenges 

Sayana Press combines a longer-acting, reversible contraceptive with the BD Uniject™ injection system developed by BD. This all-in-one prefilled, single-use, auto-disable system eliminates the need to prepare a needle and syringe. It also allows the contraceptive to be administered by a health worker outside of a clinical setting, or it can be self-injected if approved locally and after health care worker instruction. The extension of their collaboration produced a 6 year agreement, during which the price is guaranteed at $0.85. After then, Pfizer is committed to making Sayana Press affordable. 

These public- and private-sector donors and aid organizations play an important role to help ensure that women in the world’s poorest countries have access to a full range of contraceptive options. In addition to assisting with procurement, these organizations support country introductions and the delivery of a range of high quality modern contraceptive options, including subcutaneous injectable contraceptives. At the country level, the organizations also work with local governments with the goal of including modern contraceptives in reproductive health plans and budgets, coordinating health-worker trainings to improve quality counselling and services, and raising awareness about the availability of a variety of modern contraceptive options. 

Partner Involvement

Additional collaborators supporting efforts to increase access to a full range of modern contraceptives include public- and private-sector donors and aid organizations such as United Kingdom’s Department for International Development (DFID), UNFPA, the United Nations Population Fund, and the United States Agency for International Development (USAID). BD (Becton, Dickinson & Company) is the manufacturer of the delivery system.

The public- and private-sector donors and aid organizations supporting this effort to increase access to a full range of contraceptives first collaborated in 2014 to assess demand for subcutaneous injectable options, including Pfizer’s all-in-one injectable contraceptive, Sayana® Press (medroxyprogesterone acetate) for women most in need in some of the world’s poorest countries. In 2017, Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation announced a multi-year extension of their collaboration to further broaden access to Sayana Press. Sayana Press will now be available to qualified purchasers at a guaranteed price of US $0.85 per dose, a reduction from the previous price of US $1.00 per dose.

List of countries involved

Some of the world’s poorest countries, including countries outlined in FP2020 a global collaboration to help ensure that by 2020, an additional 120 million women have the ability to access and voluntarily use a method of modern contraception.

Lessons learned

The public- and private-sector donors and aid organizations first collaborated in 2014 to assess demand for subcutaneous injectable contraceptives, including Sayana Press. Initial pilots conducted in Niger, Senegal and Uganda demonstrated strong demand for subcutaneous inectable contraceptives among younger women: up to 34 percent of doses administered across these three countries were to women between the ages of 20 and 24. Sayana Press is also attracting women who have never before used contraceptives, with 24- 42% of doses given across the pilots received by new users of family planning. [iii]

By working together to expand the range of contraceptive options available, more women in more countries have had access to them, including Sayana Press every year. 

Summary of impact and forward looking information

By the end of 2016, 6.4 million units of Sayana Press were shipped to 20 developing world countries, potentially reaching more than 1.5 million women – up from 350,000 women at the end of 2014[iv]. Pfizer is continuing to make investments in its manufacturing facilities to meet the expected increase in market demand.  

Measurement of progress towards objectives 

  • Estimated overall value of partnership: Sayana Press will now be available to qualified purchasers at a guaranteed price of US $0.85 per dose, a reduction from the previous price of US $1.00 per dose.
  • Estimated amount of people impacted: By the end of 2016, 6.4 million units of Sayana Press were shipped to 20 developing world countries, potentially reaching more than 1.5 million women

 

[i] World Health Organization. Family Planning/Contraception Fact Sheet. Available at: http://who.int/mediacentre/factsheets/fs351/en/. Accessed: February 22, 2017. 

[ii] UNFPA. Family Planning. Available at: https://www.unfpa.org/family-planning. Accessed: February 23, 2017.

[iii] PATH. Monitoring Sayana Press Pilot Introductions. Available at: http://www.path.org/publications/files/RH_sayana_press_pilot_intro_2017.pdf. Accessed: May 2, 2017.

[iv] Data on file at Pfizer Inc. Where a woman is assumed to have used 4 doses of the total units shipped in 2014; where each woman is assumed to have used 4 doses of the total number shipped (2014-2016).
 

Partnership information

Company(ies) Pfizer

Partner(s) BD (Becton Dickinson), Bill and Melinda Gates Foundation, Children’s Investment Fund Foundation, UK Department for International Development (DFID), UNFPA, United Nations Population Fund, US Agency for International Development (USAID)

Type of Partner(s) Government, IGOs, NGOs, Other Business

Therapeutic Focus Women and Children's Health

Disease(s) Family Planning, Sexual & Reproductive Health, Women's Health

Program Type(s) Availability of Treatment - Financial Support

Region(s) World

Number of Countries 1

Country(ies) Worldwide

Start Date 2014

Anticipated completion date Ongoing

« Our hope is that more women in the developing world will now have access to Sayana Press, as an option, to meet their specific family planning needs. By improving access to contraceptive options, we can help empower women most in need. »

John Young, President, Pfizer Essential Health